Transaction in own shares

Arix Bioscience PLC (ARIX) Transaction in own shares 31-March-2021 / 17:38 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Arix Bioscience plc Transaction in own shares LONDON, 31 March 2021: Arix Bioscience plc ("Arix" or "the Company"), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that it purchased the following number of its ordinary shares of 0.001 pence each on the London Stock Exchange from Jefferies International Limited as part of a buyback programme announced on 22 March 2021. Date of purchase 31 March 2021 Aggregate number of shares purchased 85,000 Highest price paid per share 190.50p Lowest price paid per share 186.50p Average price paid per share 189.28p Arix intends to retain the purchased shares in treasury. Following settlement of the above purchase, Arix will have 134,980,653 ordinary shares of 0.001 pence each in issue (excluding 629,000 ordinary shares of 0.001 pence each held in treasury). This number represents the total voting rights in Arix and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.  In accordance with Article 5(1)(b) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), the schedule below contains detailed information of the individual trades made by Jefferies International Limited as part of the buyback programme. [ENDS] For more information on Arix, please contact: Arix Bioscience plc Charlotte Parry, Head of Investor Relations [phone] [e-mail] Optimum Strategic Communications Mary Clark, Supriya Mathur, Shabnam Bashir [phone] [e-mail] About Arix Bioscience plc Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences. We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com Transaction Date Transaction Time Volume Price (GBp) Platform Transaction Reference Number 31/03/2021 10:14:21 6,500 186.50 London Stock Exchange 00232750590TRLO0 31/03/2021 10:23:56 1,500 187.00 London Stock Exchange 00232756281TRLO0 31/03/2021 11:03:20 5,000 187.00 London Stock Exchange 00232780610TRLO0 31/03/2021 11:10:24 8,212 187.00 London Stock Exchange 00232784819TRLO0 31/03/2021 13:27:14 2,000 188.00 London Stock Exchange 00232864456TRLO0 31/03/2021 14:49:17 1,460 189.00 London Stock Exchange 00232932126TRLO0 31/03/2021 15:23:00 25,000 190.50 London Stock Exchange 00232969192TRLO0 31/03/2021 15:33:38 1,000 189.00 London Stock Exchange 00232981142TRLO0 31/03/2021 15:39:15 10,000 190.00 London Stock Exchange 00232987691TRLO0 31/03/2021 16:05:21 24,328 190.00 London Stock Exchange 00233018688TRLO0 ISIN: GB00BD045071 Category Code: MSCH TIDM: ARIX LEI Code: HQCXNIX43

ISIN:	GB00BD045071
Category Code:	POS
TIDM:	ARIX
LEI Code:	213800OVT3AHQCXNIX43
OAM Categories:	2.4. Acquisition or disposal of the issuer's own shares
Sequence No.:	96753
EQS News ID:	1180324

End of Announcement	EQS News Service